V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Jazz Pharmaceuticals Executive Compensation (FY25)

JAZZ · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Renee Gala
Median of the other named officers
$6,299,539
5 officers, excluding the chief executive
Latest say-on-pay support
=
July 23, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Jazz Pharmaceuticals

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 23, 2026Latest filing (8-K): July 24, 2026
7 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Jazz Pharmaceuticals brief$1,500Get the executive brief
Velarion Member, one year
340 figures on this page: 337 cited to the filing that reported them, 3 calculated from figures it prints. See the citations

More on Jazz Pharmaceuticals

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
CEO pay ratio: 55:1 → 69:1 (25.5% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Jazz Pharmaceuticals' chief executive and what were they paid?
Renee Gala was paid $19,151,558 in total compensation as President, CEO and Director for fiscal 2025.
What was Jazz Pharmaceuticals' say-on-pay result?
Shareholders supported the say-on-pay proposal with 93.8% of votes cast for or against in favor at the meeting held July 23, 2026 for fiscal 2025.
Which companies are in Jazz Pharmaceuticals' peer group?
The disclosed peer group names Alkermes plc, Alnylam Pharmaceuticals, Inc., Biogen, Inc., BioMarin Pharmaceutical Inc. and Exelixis, Inc., among others.
What is Jazz Pharmaceuticals' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 69:1, against median employee compensation of $281,424.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Bruce Cozadd
Chairman and Chief Executive Officer
◇—◇—◇—◇◇
Daniel Swisher Jr.
President, COO
◇—◇—◇—◇◇
Renée Galá
Executive Vice President and Chief Financial Officer
◇—◇—◇—◇◇
Robert Iannone
Executive Vice President, Research and Development and Chief Medical Officer
◇—◇—◇—◇◇
Kim Sablich
Executive Vice President and General Manager, US
◇—◇—◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Bruce Cozadd
Chairman and Chief Executive Officer
◇—◇—◇—◇◇
Daniel Swisher
Executive Vice President and Chief Commercial Officer
◇—◇—◇—◇◇
Renée Galá
President and COO
◇—◇—◇—◇◇
Robert Iannone
Executive Vice President, Research and Development and Chief Medical Officer
◇—◇—◇—◇◇
Neena Patil
Executive Vice President and Chief Legal Officer
◇—◇—◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Bruce Cozadd
Chairperson and Former CEO
◇—◇—◇—◇◇
Renée Galá
President, CEO and Director
◇—◇—◇—◇◇
Robert Iannone
Executive Vice President, Global Head of Research and Development and Chief Medical Officer
◇—◇—◇—◇◇
Philip Johnson
Executive Vice President and CFO
◇◇◇—◇—◇◇
Samantha Pearce
Executive Vice President, Chief Commercial Officer
◇◇◇—◇—◇◇
Neena Patil
Executive Vice President and Chief Legal Officer
◇—◇—◇—◇◇
Patricia Carr
Senior Vice President, Chief Accounting Officer
◇—◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Renee Gala
President, CEO and Director
◇—◇—◇—◇◇
Bruce Cozadd
Chairperson and Former CEO
Departed during or after this year
◇◇◇◇——◇◇
Robert Iannone
Executive Vice President, Global Head of Research and Development and Chief Medical Officer
◇—◇—◇—◇— not reconciled
Philip Johnson
Executive Vice President and CFO
◇—◇—◇—◇◇
Neena Patil
Executive Vice President and Chief Legal Officer
◇—◇—◇—◇◇
Samantha Pearce
Executive Vice President, Chief Commercial Officer
◇—◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Bruce C. CozaddRSU◇——◇——◇
Bruce C. CozaddRSU◇——◇——◇
Neena M. PatilPSU◇◇◇—◇—◇
Neena M. PatilRSU◇——◇——◇
Neena M. PatilRSU◇——◇——◇
Philip L. JohnsonRSU◇——◇——◇
Philip L. JohnsonRSU◇——◇——◇
Philip L. JohnsonPSU◇◇◇—◇—◇
Renee D. GalaRSU◇——◇——◇
Renee D. GalaRSU◇——◇——◇
Renee D. GalaRSU◇——◇——◇
Renee D. GalaPSU◇◇◇—◇—◇
Renee D. GalaPSU◇◇◇—◇—◇
Robert IannonePSU◇◇◇—◇—◇
Robert IannoneRSU◇——◇——◇
Robert IannoneRSU◇——◇——◇
Samantha PearcePSU◇◇◇—◇—◇
Samantha PearceRSU◇——◇——◇
Samantha PearceRSU◇——◇——◇
Fiscal 2022, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Neena PatilRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
Renee GalaPSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
Bruce CozaddRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
Philip JohnsonPSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
Samantha PearcePSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Robert IannoneRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Rick E Winningham
Lead independent director
◇◇————◇
Heather Ann McSharry
◇◇————◇
Jennifer E. Cook
◇◇————◇
Norbert G. Riedel
◇◇————◇
Patrick Kennedy
◇◇————◇
Seamus C. Mulligan
◇◇————◇
Patrick G. Enright
◇◇————◇
Anne O'Riordan
◇◇————◇
Mark D. Smith
◇◇————◇
Laura J. Hamill
◇◇————◇
Kenneth W. O'Keefe
◇◇————◇
Ted W. Love
◇—————◇
Bruce C. Cozadd and Renee D. Gala served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Alkermes plc ALKS
  • Alnylam Pharmaceuticals, Inc. ALNY
  • Biogen, Inc. BIIB
  • BioMarin Pharmaceutical Inc. BMRN
  • Exelixis, Inc. EXEL
  • Gilead Sciences, Inc. GILD
  • Incyte Corporation INCY
  • Moderna, Inc. MRNA
  • Neurocrine Biosciences, Inc. NBIX
  • Organon & Co. OGN
  • Regeneron Pharmaceuticals, Inc. REGN
  • United Therapeutics Corporation UTHR
  • Vertex Pharmaceuticals Incorporated VRTX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025July 23, 2026=◇◇◇
2024July 24, 2025=◇◇◇
2023July 25, 2024=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Renee Gala (President, CEO and Director), FY2025 total compensation $19,151,558 (base salary $1,003,269) [exec_comp, SEC accession 0001232524-26-000029, filed 2026-06-08]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Tell me when Jazz Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Jazz Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Jazz Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Jazz Pharmaceuticals' disclosed peer group is defensible, who names Jazz Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
340 figures on this page: 337 cited to the filing that reported them, 3 calculated from figures it prints.
337 cited to the filing
3 calculated from the filing

Documents cited

  1. 0001628280-26-049466
    Proposal 3 was to approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.
  2. 0001232524-26-000029
    CEO Pay Ratio · DIRECTOR COMPENSATION · Director Compensation · Director Compensation for Fiscal 2025 · and 3 more sections
  3. 0001232524-25-000051
    Proposal 3 was to approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement.
  4. 0001232524-25-000043
    Summary Compensation Table
  5. 0001232524-24-000056
  6. 0001232524-24-000049
    Summary Compensation Table
  7. 0001193125-23-168992
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Jazz Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/JAZZ (accessed 2026).
Short form: data: Velarion

The paid brief for Jazz Pharmaceuticals

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Jazz Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Jazz Pharmaceuticals discloses

The companies named in JAZZ's own disclosed peer group.

Alkermes plcAlnylam Pharmaceuticals, Inc.Biogen, Inc.BioMarin Pharmaceutical Inc.Exelixis, Inc.Gilead Sciences, Inc.Incyte CorporationModerna, Inc.Neurocrine Biosciences, Inc.Organon & Co.Regeneron Pharmaceuticals, Inc.United Therapeutics CorporationVertex Pharmaceuticals Incorporated

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy